Oral, rather than subcutaneous, methotrexate avoids weekly injections, reduces costs and might improve quality of life in children with Crohn's disease. 226 children with Crohn's disease were included in a study to assess methods of administration of this drug. The subcutaneous route was found to be superior to oral administration; however, the authors highlight that these findings were only true for some outcomes, and with a modest effect size. In some children in complete remission, it might be reasonable to consider switching from subcutaneous to oral methotrexate, although close monitoring is needed.